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Bovine milk exosomes (BMEs) have attracted attention as vehicles for delivering RNA
therapeutics. BMEs originate in mammary alveolar cells. Here, we determined whether bovine
mammary alveolar MAC-T cells are a promising tool to assess RNA delivery by BMEs. MAC-T
cells exosomes (MAC-T BMEs) and BMEs were harvested by differential ultracentrifugation.
Exosome size, morphology, microRNA content and marker proteins were assessed using
nanoparticle tracking analysis, transmission electron microscopy, real-time PCR and immunoblot
analysis, respectively. MAC-T cells were genetically engineered to secrete MAC-T BMEs
endogenously labeled with a near-infrared fluorescent protein and tissue distribution was
compared to fluorophore-labeled BMEs following intravenous injection in C57BL/6 mice.
Morphology and size were similar in MAC-T BMEs and BMEs (94 ± 5.8 nm and 101 ± 4.2 nm,
p > 0.05). Both preparations expressed miR-320a, miR-200c and let-7a-5p (positive controls) but
not miR-1 (negative control). Exosome marker proteins, CD9, CD63, CD81 and Tsg101, were
detected in both MAC-T BMEs and BMEs. The distribution in mouse tissues was similar for
both preparations, with liver being the primary accumulation site. Collectively, MAC-T BMEs
are a promising tool for BMEs-based RNA delivery studies.
Key words: Bovine mammary alveolar MAC-T cells; bovine milk exosomes; CD81 fusion
protein; drug delivery; RNA; transgenic
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CHAPTER ONE
INTRODUCTION
Limitations of conventional cancer therapy
Although advanced understanding of cancer biology has led to the development of improved
cancer therapeutics, cancer remains one of the leading causes of death worldwide due to
unfavorable pharmacokinetics of therapeutics [1] [2].
Chemotherapy is the most common type of cancer therapy, and it employs free anticancer drugs
and, more recently, RNA therapeutics (such as siRNA) to inhibit cancer progression [3]. siRNA
is of particular importance because of their ability to stop tumor progression at the molecular
level by knocking down key genes that govern cell proliferation, angiogenesis, metastasis and
apoptosis [4]. However, the therapeutic index of free anticancer drugs and unmodified RNA
therapeutics is suboptimal due to their non-specificity for tumor cells, rapid systemic clearance
by the reticuloendothelial cells, unstable physicochemical properties, off target effects, rapid
clearance by the reticuloendothelial cells, reduced therapeutic concentrations in target cells, and
uniform distribution to both diseased and normal cells resulting in dose-limiting toxicity [5] [6]
[7]. Hence, a protective and targeted delivery system is needed to improve their therapeutic
effects [1].
Nanoparticles- mediated drug delivery
The application of nanoparticle mediated drug delivery significantly enhanced the therapeutic
potential of therapeutics by increasing their systemic stability allowing for their increased
accumulation at the target site [8]. Typically, nanoparticles are small sized (20 nm-500 nm)
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particles that possess interior core for drug packaging and an exterior core that can be decorated
with functional peptides [9]. The small size of nanoparticles enables them to evade systemic
clearance while their interior core confers stability and protection on encapsulated drugs and
nucleic acids [10]. Synthetic lipid nanoparticles such as liposomes and polymeric micelles were
the first to be explored in nanoparticle-based therapy and have been approved for clinical use
[11]. Synthetic nanoparticles have substantially improved the efficacy of anticancer agents and
therapeutics by increasing their therapeutic concentrations at the target site and reducing the offtarget side effects [6]. However, they are fraught with issues such as inefficient cargo delivery,
formation of aggregates, induction of immune response, systemic toxicity, and poor stability
[12]. In contrast, exosomes have natural ability to protect and deliver functional biomolecules to
target cells with low immunogenicity [13]. Hence, they have recently gained traction in the
pharmaceutical industry as potential drug packaging and delivery systems [14-16].
Exosomes are natural extracellular nanoparticles (30-150 nm) secreted by virtually all cell types
for cell-to-cell communication. [17]. Their formation is highly coordinated: first, the endosomal
membrane invaginates to form intraluminal vesicles (ILVs) enclosed within large multivesicular
bodies (MVBs); these MVBs then either fuse with the plasma membrane to release ILVs into the
extracellular space as exosomes or are mobilized for lysosomal degradation [18, 19]. Before their
release into the extracellular space, labile cargos such as miRNAs, lipids and proteins are
selectively incorporated into exosomes [20] (Fig 1.). Intracellular communication is achieved
through the interaction of exosomes with the surface of recipient cells or the delivery of regulatory
cargos (miRNAs) to recipient cells [21, 22]. Exosomes have an advantage over synthetic
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nanoparticles in targeted drug delivery because they are more natural, stable, bioavailable and less
toxic compared to synthetic nanoparticles. [23, 24].

A

B

Figure 1. 1 Formation of exosomes and their secretion into the extracellular. Exosomes’ uptake
and cargo release in recipient cells space (A). Their release into the extracellular space (B).
Adapted from Raposo et al., 2013 [25].
Exosomes from different sources such as milk, plasma and cell cultures have been explored for
clinical translatability [24] (Fig. 2). This is necessary because exosomes possess a repertoire of
cell-specific lipids and protein markers on their surface that determine their biological functions
and tissue distribution pattern in-vivo [26]. For instance, tumor cell derived exosomes contain
tumor associated biomolecules that induce metastatic behavior in normal cells [27]. Also,
exosomes secreted by dendritic cells carry antigens that stimulate immune responses [28]. It is
therefore crucial to carefully assess the biological properties and functions of exosomes and their
progenitor cells so as to avoid occurrences that would jeopardize the intended therapeutic effects
[26].
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Figure 1. 2 Exosomes sources and their advantages. Bovine milk exosomes have superior drug
delivery properties than exosomes secreted by cancer cells and dendritic cells. Illustration
created with BioRender.com
Bovine milk exosomes for drug delivery
Bovine milk exosomes (BMEs) are extensively explored as promising vehicles for the delivery of
RNA therapeutics due to their high yield, safety, cost effectiveness and natural ability to deliver
functional biomolecules to target cells [29, 30]. BMEs are generally considered safe for drug
delivery because of the prominent role of bovine milk in human nutrition [31]. Moreover, previous
studies have reported that BMEs do not elicit significant immunogenic effect in humans and rats
[32]. Bovine milk is cheap, readily accessible in most geographical regions and is a scalable source
of exosomes [33]. Our lab has previously demonstrated that BMEs and their miRNA cargos are
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absorbed and transported by endocytosis in human endothelial cells [34]. Baier et al. were the first
to report a postprandial increase in plasma concentration of milk miRNA following milk
consumption [21]. Also, Manca et al. revealed that synthetic miRNAs encapsulated within BMEs
could be delivered to the liver, intestinal tract, brain, and spleen in mice [35]. Mature miRNAs
are non-coding RNAs (~22 nucleotides in length) that can degrade mRNAs or inhibit their
translation depending on their complementarity [36-38]. Approximately 60 % of human genes are
regulated by miRNAs [39]. BMEs can overcome placenta barrier [40]. Sadri et al., reported that
BMEs-mediated delivery of synthetic miRNAs (miR-21-5p and miR-30d) elicited gene expression
changes in murine placenta and increased fetal implantation [41]. It was recently reported that
encapsulation of siRNA into BMEs facilitated their intracellular delivery and gene silencing
activity in HEK293 cells [42]. These attributes make BMEs attractive vehicle for targeted delivery
of drugs and therapeutic nucleic acids to diseased tissues.
The traditional approach of studying BMEs is fraught with huge variability and inefficient due to
the challenging isolation and limited cargo loading procedure. The reason being that BMEs quality
and their cargo profiles are significantly affected by several factors such as the physiological state
of their parent cells, isolation techniques and sample processing [43]. The common isolation
techniques such as ultracentrifugation, density gradient centrifugation, salting out and size
exclusion allow enrichment of exosomes but with low purity as natural bovine milk contains stable
multi-protein complexes that share comparable size with BMEs. Some free proteins even
specifically complex with BMEs surface and co-precipitate during isolation procedure causing
confounding effects on downstream analyses [44]. Also, the current loading of functional
biomolecules into BMEs is passive and too inefficient for targeted drug delivery. Passive loading
entails encapsulation of biomolecules into purified exosomes by electroporation, repeated freeze
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thawing, sonication, or even extrusion of natural cargos for a more functional one [45]. During
this loading process, the exosomes membrane is temporarily disrupted and incubated with
functional biomolecule which diffuses into the interior through the pores created on the exosomes.
The major limitations of this method are as follows: (1) it is non-targeted; (2) loading efficiency
depends on diffusion through a concentration gradient and the interaction between biomolecules
and the phospholipid membrane of the exosomes; (3) It may lead to distortion of exosomes
integrity. [26, 46, 47]
To accelerate BMEs studies for targeted therapeutic application, there is need to employ a more
controlled in vitro cell system that will ensure reproducible isolation of pure BME preparations
and allow functional biomolecules to be efficiently loaded into BMEs using gene technology [48].
Bovine mammary epithelial cell (MAC-T) is the functional unit of milk secretion and the primary
origin of milk exosomes [49]. MAC-T cell is widely regarded as a reliable in vitro model for the
studies of mammary gland functions because of its expression of milk-specific proteins [50] and
thus is ideal for studying genetic modifications in BMEs.
Many studies have explored the surface modification of exosomes for imaging and targeting
purposes using genetic engineering. Genetic engineering of donor cells for exosomal cargo loading
offers the following benefits: ability to load encodable targeting ligands, imaging agents,
antibodies or other functional biomolecule into exosomes with high efficiency, precision and
specificity; minimal interference with exosomes surface proteins; and the flexible packaging of
biomolecules in the interior and/or exterior surface of exosomes [48]. To genetically modify
exosomes, the transgene is first fused to exosome-specific markers such as CD81, CD9 and CD63
etc. and then expressed in the donor cells by plasmid transfection. Transformed donor cells then
secrete engineered exosomes with the functional protein attached to their surface [51]. For
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example, previous studies have produced brain targeting dendritic cell-derived exosomes by
expressing a fusion of the central nervous system specific rabies viral glycoprotein (RVG) peptide,
and exosomes specific protein, Lamp2b, in murine dendritic cells. The transformed dendritic cells
secreted RVG-exosomes that crossed the blood-brain barrier (BBB). When loaded with β-site
amyloid precursor protein cleaving enzyme 1 (BACE1) siRNAs, these engineered exosomes
delivered their cargos to brain cells where they induced a 62% reduction in BACE1 mRNA
expression [52]. Another study expressed a fusion protein consisting of ischemic myocardium‐
targeting peptide (IMTP) and Lamp2b in bone marrow mesenchymal cells (BMSCs) and the
transformed cells secreted engineered exosomes that showed increased uptake by ischemic
myocardium compared to unmodified exosomes [53]. Aside from the packaging of targeting
peptides, donor cells can be genetically modified to load highly sensitive fluorescent proteins into
exosomes

to

visualize

and

monitor

their

biodistribution,

viability,

and

biological

activity/therapeutic efficiency in vivo [35, 54]. Traditionally, fluorescent lipophilic dyes are used
to label BMEs, but this labelling approach is inefficient due to non-specificity, release of dyes
from exosomes membranes, long half-life of chemical dyes and generation of non-exosomes
related signals [55]. In contrast, gene labeling technology increases the stability and exosomespecificity of fluorescent proteins thereby providing an accurate assessment of the spatiotemporal
distribution of exosomes [56, 57]. Some studies have endogenously labeled exosomes by fusing
fluorescent transgenes such as eGFP, RFP, iRFP, Zsgreen1, exosomes-enriched markers such as
CD63, CD9, CD81 [35, 58, 59].
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Abstract
Bovine milk exosomes (BMEs) have attracted attention as vehicles for delivering RNA
therapeutics. BMEs originate in mammary alveolar cells. Here, we determined whether bovine
mammary alveolar MAC-T cells are a promising tool to assess RNA delivery by BMEs. MAC-T
cells exosomes (MAC-T BMEs) and BMEs were harvested by differential ultracentrifugation.
Exosome size, morphology, microRNA content and marker proteins were assessed using
nanoparticle tracking analysis, transmission electron microscopy, real-time PCR and immunoblot
analysis, respectively. MAC-T cells were genetically engineered to secrete MAC-T BMEs
endogenously labeled with a near-infrared fluorescent protein and tissue distribution was
compared to fluorophore-labeled BMEs following intravenous injection in C57BL/6 mice.
Morphology and size were similar in MAC-T BMEs and BMEs (94 ± 5.8 nm and 101 ± 4.2 nm,
p > 0.05). Both preparations expressed miR-320a, miR-200c and let-7a-5p (positive controls) but
not miR-1 (negative control). Exosome marker proteins, CD9, CD63, CD81 and Tsg101, were
detected in both MAC-T BMEs and BMEs. The distribution in mouse tissues was similar for
both preparations, with liver being the primary accumulation site. Collectively, MAC-T BMEs
afford are a promising tool for BMEs-based RNA delivery studies.
Key words: Bovine mammary alveolar MAC-T cells; bovine milk exosomes; CD81 fusion
protein; drug delivery; RNA; transgenic
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Introduction
Nanoparticles are promising tools for delivering therapeutics, including the delivery of small
interfering RNA (siRNA) to sites of disease such as tumors [1]. Nanotechnology offers a variety
of advantages compared to the conventional method of delivering free drugs. For example,
nanoparticles may facilitate the transfer of therapeutics across the blood-brain barrier and protect
unstable RNA cargos against degradation [2, 3]. When self-derived exosomes from dendritic
cells, modified by a brain homing peptide, rabies virus glycoprotein, were loaded with BACE1
siRNA and delivered by intravenous injection, the expression of BACE1 mRNA and protein
decreased by 60% in neurons, microglia, oligodendrocytes and their precursors [4]. The
technology was subsequently applied in the knockdown of other gene targets in mice and allelespecific knockdown of oncogenic KRASG12D in mouse models of pancreatic cancer [5-7]. While
the production of cell culture-derived exosomes is a promising technology, their use in drug
delivery poses challenges such as limited drug loading efficiency and lack of standardized
isolation and purification methods [8].
Bovine milk exosomes (BMEs) have attracted attention for use in drug delivery because of the
following observations. BMEs and their RNA cargos are bioavailable after oral administration
and cross the blood-brain barrier (BBB) in humans, mice and pigs [9-11]. The cellular uptake of
BMEs is facilitated by endocytosis in endothelial cells [12]. BMEs confer protection to RNA
cargos against the harsh conditions encountered in the gastrointestinal tract (low pH, RNase) and
in industrial processing of milk [13, 14]. BMEs may be loaded with small RNAs by using
calcium chloride and ethanol [11]. BMEs do not elicit a significant immune reaction in humans
in vivo and ex vivo, and in rats [15, 16], which is an important consideration when pursuing
federal approval of a drug [17]. The production of BMEs is scalable. On average, a cow
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produces 10,800 kg of milk annually in the U.S. in 2020, and milk contains approximately 1012
exosomes per milliliter [13, 18].
Here, we sought to establish a tool that accelerates the rate of discovery in drug delivery by
BMEs by comparing morphology, size and content and tissue distribution in BMEs and
exosomes secreted by bovine mammary alveolar MAC-T cells [19], and by assessing whether
MAC-T cells and their exosomes are amenable to genetic engineering. MAC-T cells were chosen
as cell model because evidence suggests that BMEs originate in bovine mammary alveolar cells
[20, 21].
Materials and Methods
Cell Cultures
Bovine mammary alveolar MAC-T cells were derived from primary bovine mammary alveolar
cells and immortalized using SV-40 large T antigen [19]. The MAC-T cells were a kind gift by
Dr. Thomas McDonald at the University of Nebraska Medical Center. MAC-T cells were
cultured as previously described [19]. Briefly, MAC-T cells were plated in T175 flasks (cat. #
12-556-011, Thermo Scientific) at a density of 2.5 x 106 in Dulbecco’s modified eagle medium
(DMEM) (cat. # SH30284.02, Cytiva) supplemented with 10% fetal bovine serum (cat. # S1150Nov, Novus Biologicals), 5 µg/ml Insulin (cat. # 91077C-100MG, Sigma-Aldrich), 1 µg/ml
hydrocortisone (cat. # H0396, Sigma-Aldrich) and 1% penicillin-streptomycin mixture (cat. #
17-602E, Lonza). The fetal bovine serum was conditioned by depleting exosomes through
centrifugation at 120,000 g for 18 hours.
Exosome Isolation and Authentication
Exosomes were isolated from of MAC-T cell culture-conditioned media (containing exosomedepleted fetal bovine serum) and store bought bovine milk by differential ultracentrifugation
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using a F37L-8×100 rotor as previously described [10]. Hereafter, we refer to MAC-T cell
derived exosomes as MAC-T BMEs. Protocol details are available through the EV-Track
database (ID: EV210158). Purified exosome pellets were resuspended in 500 µl of phosphate
buffered saline and stored at -80oC until analysis unless stated otherwise.
MAC-T BMEs and BMEs were thawed at room temperature and diluted as required for
assessment of size and count by using a NanoSight NS300 tracking instrument (Malvern,
Westborough, MA). We used the following instrument settings: camera level 14, detection
threshold 5, syringe speed 100 and five 1-minute videos (technical replicates) per biological
replicate (n = 3). Data were analyzed by using NTA 2.3 software (Malvern).
Morphology and dispersion of exosomes were assessed by using transmission electron
microscopy [22]. Briefly, the exosomes were fixed, stained with phosphotungstic acid (3 mM),
and analyzed as previously described using a Hitachi H7500 microscope in the Nebraska
Microscopy Core at the University of Nebraska-Lincoln.
Exosomes were further authenticated by immunoblot analysis using positive and negative marker
proteins as follows [23]. Protein extraction and analysis were performed as previously described
by [10]. Protein concentrations were assayed by using the bicinchoninic acid assay (cat. # HYK1001, MedChem Express) and 50 µg total protein from exosomes and cell lysates were
separated on 4-12% Bis-Tris Protein Gels (cat. # NP0322, Thermo fisher). Transblots on PVDF
membranes were probed with the following antibodies: mouse anti-bovine CD9 (cat. #
GTX76185, Genetex), mouse anti-bovine CD63 (cat. # MCA2042GA, BioRad), rabbit antihuman CD81 (cat. # ab 155760, Santa Cruz) and rabbit anti-bovine TSG101 (cat. # sc-7964,
Santa Cruz) as exosome markers; and rabbit anti-mouse calnexin (cat. # ab7580, Abcam,) as a
negative control. Protein bands were visualized by using IRDye 800CW-conjugated goat anti-
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mouse (cat. # 926-32210, LI-COR Biosciences) or IRDye 800CW-goat anti-rabbit (cat. # 92632211, LI-COR Biosciences) and an Odyssey Clx Imaging System (LI-COR, Inc. Biosciences).
MicroRNA Analysis
Quantitative real time PCR (qPCR) was used to assess the presence of microRNAs in MAC-T
cell exosomes as previously described [24]. Cel-miR-39 was added to the samples during the
isolation process as a spike-in control for the efficiency of RNA extraction and cDNA synthesis
[9]. The expression levels of three milk enriched microRNAs, miR-320a, miR-200c and let-7a5p were assessed by qPCR using the universal reverse primer in the miScript SYBR Green PCR
kit (cat. # 218073, Qiagen) and microRNA-specific forward primers (Table S. 1). MiR-1 is not
present in BMEs and was used as negative control [9]. Cycle threshold (Ct) values greater than
29 were considered not detectable (N.D.) [25].
Genetically Engineered MAC-T Cells
MAC-T cells were genetically engineered to secrete transgenic exosomes containing a fusion
protein composed of the tetraspanin CD81, near-infrared fluorescent protein (iRFP) and a
polyhistidine tag (Supplementary Fig. 1). CD81 is a well-established exosome marker [26]. The
feasibility of labeling CD81 through a fusion of a fluorescent protein to the C-terminus was
previously demonstrated [27]. The design of the plasmid positions iRFP and polyhistidine inside
exosomes, which minimizes the impact on the outer exosome surface and therefore tissue
distribution [28]. iRFP has physicochemical properties conducive to successful tracking of
exosomes in animals, e.g., minimal photodamage, low auto-fluorescence and deep tissue
penetration [29, 30]. To construct the plasmid, individual fragments of bovine CD81 (726 bp)
and iRFP (978 bp) were amplified from MAC-T cell cDNA and piRFP plasmid (cat. # 31857,
Addgene), respectively, using Q5 High-Fidelity DNA Polymerase kit (cat. # M0491S, New
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England Biolabs) and the PCR primers shown in Supplementary Table 2. The open reading
frame encoding the CD81-iRFP-polyhistidine fusion protein (1704 bp) was obtained by joining
the PCR products using overlap PCR [31] with the primers denoted CD81_forward and
iRFP_His reverse in Supplementary Table 2. The following program was used for overlap PCR:
initial denaturation at 98°C for 2 minutes followed by 17 cycles of 98°C for 15 seconds
(denaturing), 67°C (−0.5°C/cycle) for 15 seconds (annealing) and 72 °C for 30 seconds
(extension). The first round of PCR was followed by another 23 cycles: 98°C for 15 seconds
(denaturing), 59°C for 15 seconds (annealing), 72°C for 45 seconds (extension) and a final
denaturation step at 72°C for 2 minutes. The product was cloned into a pCDH-puro lentiviral
plasmid (cat. # 46970, Addgene, Watertown, MA). Absence of mutations was confirmed by
sequencing analysis and the plasmid is hereafter referred to as pCDH-CD81-iRFP
(Supplementary Fig. 1).
The pCDH-CD81-iRFP plasmid, envelope plasmid (pMD2.G, cat. # 12259, Addgene) and
packaging plasmid (psPAX2, cat. # 1226, Addgene) were co-infected into HEK-293T cells using
attractene (cat. # 301005, Qiagen), following the manufacturer’s protocol, and lentiviral particles
were collected by precipitation using standard PEG 8000 as previously described (Au - BaumlinSchmid et al. 2016). MAC-T cells were transfected with lentiviral particles using polybrene (cat
# 107689-10G, Sigma Aldrich) and stably transformed cells were selected using puromycin (2
µg/ml). MAC-T BMEs were collected by differential ultracentrifugation from 72-hour cultures
of MAC-T cells and the expression of iRFP in MAC-T BMEs and cells was assessed by using an
Odyssey Clx Imaging system (LI-COR Biosciences, Inc.).
Tissue Distribution of MAC-T BMEs in Mice
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We compared the tissue distribution of iRFP-labeled MAC-T BMEs and HiLyte-labeled BMEs
in C57BL/6 mice at 6 weeks of age (Jackson laboratory, stock number 000664) were assessed
and compared. BMEs were labeled with carbonyl-reactive HiLyte 750 (cat. # 61183, AnaSpec
Inc., San Jose, CA) following the manufacturer’s recommendations. We chose a dose of 1 x 1011
exosomes/g body weight for tail vein injection of iRFP-labeled MAC-T cell BMEs, HiLyte 750labeled BMEs and controls (unlabeled MAC-T BMEs and unlabeled BMEs) based on the
rationale that the dose produced a robust signal in a previous study [11]. The mice were
euthanized 3 hours after injection when tissues were excised and washed with cold phosphate
buffered saline. iRFP and HiLyte 750 fluorescence was analyzed using the 700-nm and 800-nm
filters, respectively, in an Odyssey Clx Imaging System. The fluorescence signal was corrected
by the signal from unlabeled controls. Densitometry analyses were performed by using LI-COR
Image studio 5.2 software. The percent tissue distribution was calculated by dividing the
fluorescence signal in individual tissues by the fluorescence signal from all tissues combined and
multiplying that value by 100. All animal procedures were conducted in accordance with the
University of Nebraska-Lincoln’s Institutional Animal Care and Use Committee and approved
by the Institutional Animal Care Program (protocol 1713).
Statistical Analyses
Homogeneity of variances was assessed using Levene’s test. Normality of distribution was
confirmed by using the Shapiro-Wilk test. Data analysis was performed using unpaired student’s
t test. All statistical analyses were performed using Prism 6 (Graph pad software Inc.). Data are
expressed as means ± SEM as denoted in tables and figures. Differences were considered
statistically significant if P < 0.05.
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Results
Characterization of MAC-T BMEs
The morphology and size were similar in MAC-T BMEs and BMEs from milk. Both
preparations presented as spherical membranous structures in TEM (Fig. 1). Nanoparticle
tracking analysis revealed a homogenous particle distribution with a similar mean size of 94 ±
5.8 nm and 101 ± 4.2 nm for MAC-T exosomes and BMEs, respectively (Fig. 2). Both
preparations expressed the exosome marker proteins CD9, CD63, CD81 and Tsg101 at the
expected sizes, whereas a marker of microvesicles, calnexin, was detectable only in MAC-T cell
lysate (Fig. 3).
MicroRNA Content
MAC-T BMEs and BMEs from milk expressed the three microRNAs we analyzed (positive
controls, whereas miR-1 (negative control) was not detectable (Ct > 29 cycles) in any of the
samples (Table 1). The expression of let-7a-5p and miR-200c was lower in MAC-T BMEs than
in BMEs.
Expression of CD81-iRFP-His in MAC-T cells and MAC-T BMEs
MAC-T cells were transformed to express a CD81-iRFP-polyhistidine fusion protein, which
localized to exosomes. Successful transformation and localization to exosomes was
demonstrated as follows. Transformed MAC-T cell expressed iRFP, evidenced by the emission
of near-infrared fluorescence (Fig. 4a). The image was taken after 8 passages of MAC-T cells,
consistent with stable transformation. Media from cultures of transformed MAC-T cells
produced strong near-infrared fluorescence suggesting secretion of the fusion protein by cells
into the extracellular space (Fig. 4b); media from non-transformed MAC-T cells produced no
fluorescence (control). iRFP fluorescence remained detectable in the supernatant from 16,000 g
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and 83,000 g centrifugation steps, but localized to the pellet following centrifugation at 130,000
g (Fig. 4c, depicting the pellet suspended in PBS). The vesicles in the 130,000 g pellet had a
mean size of 82 ± 1.2 nm (Fig. 5a) which is similar to exosomes secreted by non-transformed
MAC-T cells (Fig. 2). The vesicles in the 130,000 g pellet tested positive for exosome markers,
CD81 and Tsg101 (Fig. 5b). The position of the CD81 band was as expected for a CD81-iRFPpolyhistidine fusion protein, suggesting absence of degradation. The combination of
centrifugation and size data, as well as protein markers suggests that the CD81-iRFPpolyhistidine fusion protein localized to exosomes.
Tissue Distribution of Transformed MAC-T BMEs in C57BL/6 Mice
The tissue distribution was similar for CD81-iRFP-positive MAC-T BMEs and HiLyte-labeled
BMEs from milk following their intravenous injection in C57BL/6 mice. Both preparations
accumulated primarily in the liver, but some accumulation was also apparent in the intestinal
tract, lungs, kidneys, and spleen in both male and female mice (Fig. 6). The distribution of the
two preparations differed in a few tissues. For example, the percent accumulation in brain and
intestinal tract was higher for iRFP-labeled MAC-T BMEs than for HiLyte-labeled BMEs in
both male and female mice. HiLyte-labeled BMEs produced a stronger fluorescence signal in
murine tissues than iRFP MAC-T BMEs in both male and female mice (Supplementary Fig. 2).
Discussion
This is the first report introducing a bovine cell model amenable to genetic engineering for
studies of BMEs in drug delivery. While the use of BMEs for delivering drugs has attracted
considerable attention, previous modifications of BMEs were limited to the use of labeling and
loading strategies [11, 16, 32-34]. MAC-T cells a promising tool for accelerating the rate of
discovery in the field of BMEs and their use in nanotherapy.
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This study provides compelling evidence that morphology, size, and microRNA cargos are
similar in MAC-T BMEs and BMEs, and exosomes from both sources have comparable tissue
distribution profiles when administered intravenously to mice. MAC-T BMEs were authenticated
by following recommendations by the International Society for Extracellular Vesicles (ISEV)
[35]. Extensive authentication as well as the use of endogenous labeling approaches and the
disclosure of protocol details in the EV-Track database enhance the rigor, reproducibility and
transparency of this study.
CD81 is an exosome marker protein [26, 36]. Its choice for iRFP fusions, in addition to
precipitation in the 130,000 g fraction during ultracentrifugation, absence of precipitation at low
speed, morphology, size and marker proteins suggests that the CD81-iRFP localized to
exosomes. The demonstration that MAC-T cells are amenable to genetic engineering makes
them a potentially powerful tool in studies of nanotherapy.
This study adds to the existing body of evidence that milk exosomes originate in the mammary
gland, which was previously supported by circumstantial evidence that epithelial cells are
abundant in human milk and microRNA profiles are similar in BMEs in the lactating mammary
gland in cows [20, 21]. We acknowledge that this study does not provide an unambiguous
answer to the question where BMEs originate, but that was not this study’s goal.
This study and the use of MAC-T cells has the following limitations. The amount of BMEs
harvested from MAC-T cell cultures is small when done in a research laboratory setting. For
example, we harvested approximately 1011 MAC-T BMEs from 350 mL of culture media in 3day cultures. That said, we achieved our primary goals of characterizing exosomes from
transformed and non-transformed MAC-T cells and assessing the tissue distribution in mice,
which informs future large-scale studies. Note that the accumulation of MAC-T BMEs in the
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murine brain was considerably less than the accumulation of (allogeneic) murine milk exosomes
in the murine brain in our previous studies [11]. We propose that interactions between speciesspecific proteins on the exosome surface and the surface of receptor cells contributed to the
observed difference. The role of protein-protein interactions in facilitating cellular exosome
uptake has been reviewed [37]. Consistent with this theory, Wiklander et al. have enhanced the
accumulation of exosomes in the brain through the expression of a brain homing signal, rabies
virus glycoprotein [38]. Additional factors that might have contributed to the differences in brain
accumulation include the route and timing of exosome administration, i.e., acute intravenous
injection in this study compared to chronic oral intake in our previous study [11].
We conclude that MAC-T cells and BMEs are promising tools for optimizing drug delivery by
milk exosomes. Future studies include the assessment of oral bioavailability and immunogenic
potential of MAC-T BMEs.
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MAC-T BMEs

BMEs

Figure 2. 1 Transmission electron microscopy images of MAC-T BMEs and BMEs. Large field:
5,000-fold magnification; inserts: 20,000-fold magnification.
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Figure 2. 2 Nanoparticle tracking analysis of MAC-T BMEs and BMEs. Values are expressed as
mean ± SEM. p > 0.05 (n = 3).
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Figure 2. 3 Immunoblot analysis of protein extracts from BMEs, MAC-T BMEs, and MAC-T
cell lysate. CD9, CD63, CD81 and Tsg101 are exosome markers; calnexin is microvesicle
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Figure 2. 4 Expression of a CD81-iRFP fusion protein in genetically engineered MAC-T cells
and their exosomes. (a) Expression of CD81-iRFP in non-transformed (NT) and transformed
MAC-T cells after 8 passages. (b) CD81-iRFP in media from non-transformed and transformed
MAC-T cells. (c) Localization of CD81-iRFP signal to centrifugation fractions.
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Figure 2. 5 Authentication of engineered MAC-T BMEs. (A) Nanoparticle tracking analysis of
non-transformed (NT) MAC-T cells and transformed MAC-T cells. Values are shown as mean ±
SEM. p > 0.05 (n= 3). (B) Immunoblot analysis of CD81 and Tsg101 in exosomes from nontransformed (NT) MAC-T cells and transformed MAC-T cells.
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Figure 2. 6 Tissue distribution of iRFP-labeled MAC-T BMEs and HiLyte-labeled BMEs in
male (left) and female (right) C57BL/6 mice. The percent tissue distribution was assessed 3
hours after intravenous injection of 1.0 x 1011 exosomes/g body weight. Values are expressed as
mean ± SEM. *p > 0.005, **p > 0.0005, (n = 3).
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Figure S 1. Schematics illustration of CD81-iRFP vector construction. (A) Configuration of
CD81-iRFP plasmid construct (B) Assembly of CD81-iRFP-His fusion protein using overlap
PCR.
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Figure S 2. Biodistribution of MAC-T BMEs and HiLyte BMEs in mice tissues. Fluorescence in
excised tissues of C57BL/6 mice of after intravenous injection of iRFP MAC-T BMEs,
Unlabeled MAC-T BMEs, HiLyte BMEs and unlabeled BMEs (1 × 1011/g body weight).
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Table 2. 1 MicroRNAs in MAC-T BMEs and BMEs.
Samples

let-7a

MAC-T BMEs

28.1 ± 0.7

BMEs

23.5 ± 1.8

miR-200c
a
a

26.3 ± 0.4
21.4 ± 1.2

a
a

miR-320a

miR- 1

25.4 ± 0.8

ND

24.2 ± 1.2

ND

*Value = Ct (cycle threshold); mean ± SEM; n=3; ap ≤ 0.05 vs BMEs.
ND, not detectable.
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Table S. 1 Primers used in real-time qPCR analysis.

1

MicroRNA

Forward Primer (5’-3')1

miR-320a

AAAAGCTGGGTTGAGAGGGCGA

miR-200c

TAATACTGCCGGGTAATGATGGA

let-7a-5p

TGAGGTAGTAGGTTGTATAGTT

miR-1

TGGAATGTAAAGAAGTATGTAT

miSpike

CTCAGGATGGCGGAGCGGTCT

Qiagen’s miScript Universal Primer was used as reverse primer for all reactions. miSpike is a

synthetic microRNA used as internal control.
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Table S. 2 Primers used in building the CD81-iRFP-His construct.
Primer/ Template

Sequence (5’-3’)

Product
size (bp)

CD81_reverse

GCCGCCCGAGCCGCCGCCTGAGGAGCCGCCGTACACCGAGCTGTT

726

iRFP-His_ forward

GGCGGCTCCTCAGGCGGCGGCTCGGGCGGCGCTGAGGGAAGCGTG

978

CD81-iRFP-His_forward

GATGAATTCATGGGGGTAGAGGGCTGCACCAAG

CD81-iRFP-His_reverse

GATGGATCCCTAATGATGATGATGATGATGCTCTTCCATCACGCC

1704
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FUTURE STUDIES
BMEs have attracted attention as drug delivery vehicles because they are safe, scalable, and
bioavailable. The drug delivery potentials of BMEs are still yet to be harnessed due to limited
cargo loading and drug delivery modalities. Hence, an urgent need to explore a lab-friendly cell
model that will facilitate the genetic reprogramming of BMEs for improved drug delivery. We
addressed this lacuna by demonstrating that MAC-T cells secrete exosomes that are like BMEs,
and these cells are amenable to genetic modifications for drug delivery studies. While our
findings are a major milestone in the BMEs research community, MAC-T BMEs still merit
further exploration.
Although we showed that MAC-T BMEs exhibit similar tissue distribution patterns with BMEs,
we have not assessed their immunogenic effects in vivo. Induction of immune response is an
important phenomenon that must be avoided in drug delivery studies as this might lead to
confounding health consequences in clinical settings. Hence, this remains a fruitful line of
investigation.
Additionally, our lab has shown that orally administered BMEs and their miRNA cargos are
stable under harsh gastric conditions and penetrate the intestinal mucosa where they are absorbed
into systemic circulation. Future studies should explore the therapeutic efficacy of MAC-T
BMEs enclosed miRNA and siRNA therapeutics in the treatment of colorectal cancer and the
possibilities of moving them into clinical trials considering their safety and bioavailability
following oral intake.
This study sets the bar for the improvement of BMEs for targeted drug delivery through protein
engineering in MAC-T cells. Given the amenability of MAC-T BMEs to genetic engineering,
subsequent studies should focus on the development of trackable engineered BMEs capable of
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targeting different tissues with precision. We observed that autologous milk exosomes have
higher brain accumulation compared to exogenous exosomes. Further studies need to investigate
the surface protein(s) that are involved in their increased uptake and how it can be incorporated
into MAC-T BMEs for improved drug delivery to the brain. Currently, our lab is actively
conducting studies on genetically modified MAC-T BMEs for improved tumor targeting,
increased systemic stability, and reduced intracellular degradation. Findings from this study will
make therapeutics more effective in their target site.
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APPENDIX

Table 1. Nanosight analysis data for MAC-T BMEs and BMEs
Samples

Replicate 1

Replicate 2

Replicate 3

Mean

SEM

MAC-T BMEs

87.3

105.3

88.2

94

5.8

BMEs

97.7

108.9

95.3

101

4.2

Table 2. Nanosight analysis data for non-transformed MAC-T BMEs and transformed MAC-T BMEs.
Samples
IRFP MAC-T
BMEs
MAC-T BMEs

Replicate 1
80.4

Replicate 2
84.6

Replicate 3
82.2

Mean
82

SEM
1.2

87.3

105.3

88.2

94

5.8

Table 3. MiRNA analysis data for MAC-T BMEs and BMEs
Let 7a
MAC-T
BMEs

29.25

29.70

29.51

BMEs

27.37
27.50
22.86
20.83
27.05

27.83
27.44
23.00
20.49
27.01
miR200c

27.43
27.10
23.05
20.81
26.76

29.49
27.54
27.35
22.97
20.71
26.94

MAC-T
BMEs

27.30

27.07

27.02

27.13

BMEs

25.92
26.10
21.17
19.20
23.52

25.76
26.11
21.52
19.19
23.37
miR320a

25.48
26.12
21.31
19.24
23.60

25.72
26.11
21.33
19.21
23.50

24.42
24.60
27.05
24.04
22.29
26.49

23.97
25.06
26.87
24.02
22.36
26.35

MAC-T
BMEs

BMEs

24.71
24.88
26.96
23.94
22.23
26.29

24.37
24.85
26.96
24.00
22.29
26.38

Mean

SEM

28.13

0.68

23.54

1.80

Mean

SEM

26.32

0.40

21.35

1.23

Mean

SEM

25.39

0.79

24.22

1.18
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Table 4. Percent tissue distribution data in male and female mice.
Female Percent Tissue distribution
iRFP MAC-T BMEs

HiLyte BMEs

Replicates
Brain
5.04
Heart
0.73
Lungs
7.16
Kidneys 3.39
Spleen
2.09
Intestinal 30.70
tract

Mean
9.24 9.61 7.96
1.13 1.76 1.21
4.39 5.82 5.79
8.16 4.31 5.29
6.41 6.26 4.92
33.95 25.78 30.14

SEM
1.47
0.30
0.80
1.46
1.42
2.37

Replicates
0.09 0.12 0.12
2.88 3.88 1.90
36.37 17.61 37.68
5.20 8.19 8.38
6.68 12.04 9.27
9.40 9.71 7.33

Liver

36.71 46.45 44.69

4.19

8.81
39.37 48.45 35.32 41.05

50.90

Male Percent Tissue Distribution
iRFP MAC-T BMEs
Replicates
Brain
2.96
1.71
Heart
0.95
1.01
Lungs
7.13
6.91
Kidneys 4.98
7.10
Spleen
0.86
4.29
Intestinal 10.57
13.50
tract
Liver
72.54
65.48

Mean
0.11
2.89
30.55
7.26
9.33

SEM
0.01
0.57
6.48
1.03
1.55
0.75
3.88

HiLyte BMEs

Mean
5.58 3.42
1.35 1.10
10.42 8.15
6.32 6.13
2.28 2.48
10.53 11.53

SEM
1.14
0.12
1.14
0.62
1.00
0.98

Replicates
0.35 0.33 0.70
1.63 1.03 1.03
38.28 47.04 3.57
4.07 4.47 8.68
7.34 7.86 13.80
2.37 4.33 2.85

Mean
0.46
1.23
29.63
5.74
9.67
3.18

SEM
0.12
0.20
13.27
1.47
2.07
0.59

63.51 67.18

2.74

45.95 34.94 69.38 50.09

10.16

